Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) after reducing its price objective from $950 to $800. Following poor IL-33 data in late May ...

Here's why you should avoid REGN. Shivank Goswami Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target Regeneron highlighted that about 35% of weight loss from semaglutide alone ...

Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started ...

New findings from the EVEREST Phase 4 trial presented at the 2025 EAACI Congress reveal that Dupixent (dupilumab) significantly outperformed Xolair (omalizumab) in treating adults with severe ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...